Neoplasms, Connective Tissue: Clinical Trials

158 trials for Neoplasms, Connective Tissue, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

81 completed, 21 unknown, 20 terminated, 15 recruiting. 158 Phase 3, 21 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3158Completed 81, Unknown 21, Terminated 20, Recruiting 15, Active not recruiting 11, Withdrawn 6, Not yet recruiting 3, Suspended 1
Phase 221Completed 7, Unknown 6, Terminated 4, Recruiting 2, Active not recruiting 1, Suspended 1

Follow Neoplasms, Connective Tissue: new trials by email Literature Review of Neoplasms, Connective Tissue trials Research Report on Neoplasms, Connective Tissue

Trials (filtered) newest first · largest first

All 158 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
DEPART Study at Yale
Radiation Therapy - Dupuytren's Contracture
Phase 3Not yet recruitingYale University1582026-11-012026-10-13
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles - Osteosarcoma, Pediatric Osteosarcoma
Phase 3RecruitingGustave Roussy, Cancer Campus, Grand Paris5302026-10-072026-10-26
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Velzatinib, Imatinib - Gastrointestinal Stromal Neoplasms
Phase 3RecruitingGlaxoSmithKline8002026-07-272026-10-23
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NB003, regorafenib - GIST - Gastrointestinal Stromal Tumor, Advanced
Phase 2 / Phase 3RecruitingNingbo Newbay Technology Development Co., Ltd2552026-05-112026-11-12
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
TBI-1301, Cyclophosphamide, Fludarabine - Synovial Sarcomas
Phase 3RecruitingTakara Bio Inc.52026-01-052026-09-28
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
IDRX-42, Sunitinib - Gastrointestinal Neoplasms
Phase 3RecruitingGlaxoSmithKline4502025-12-032026-10-05
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma
Phase 2 / Phase 3TerminatedChildren's Oncology Group22025-11-102026-10-05
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
HS-20093, Gemcitabine combined with docetaxel - Osteosarcoma
Phase 3CompletedHansoh BioMedical R&D Company1222025-04-252026-10-19
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Ersodetug - Tumor Hyperinsulinism (Tumor HI)
Phase 3RecruitingRezolute162025-04-162026-09-28
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
Emactuzumab, Placebo - TGCT
Phase 3Active not recruitingSynOx Therapeutics Limited1282024-10-092026-07-29
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin - Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
Phase 3RecruitingNational Cancer Institute (NCI)3652024-09-112026-11-12
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
Phase 3WithdrawnBoehringer Ingelheim2024-06-272024-07-17
Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy
Misoprostol 200mcg Tab, Oxytocin - Myoma;Uterus
Phase 3UnknownCairo University562024-03-012024-03-22
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Ripretinib, Sunitinib - GIST
Phase 3Active not recruitingDeciphera Pharmaceuticals, LLC542023-12-132025-12-17
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
EN3835, Placebo - Plantar Fibromatosis, Ledderhose Disease
Phase 3CompletedEndo USA Inc., a Keenova Therapeutics Company4362023-11-282026-10-14
Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST
Imatinib Mesylate, Local resection - Gastrointestinal Stromal Tumor of Rectum
Phase 3Not yet recruitingFujian Medical University Union Hospital232023-10-012023-08-01
Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma
Dienogest 2 MG, N-acetyl cysteine - Uterine Leiomyoma
Phase 2 / Phase 3CompletedAin Shams University402023-09-012024-12-16
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Relugolix Combination Tablet - Uterine Fibroids, Endometriosis
Phase 3RecruitingSumitomo Pharma Switzerland GmbH10002023-08-142025-08-06
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Pimicotinib(ABSK021), Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis
Phase 3Active not recruitingAbbisko Therapeutics Co, Ltd942023-04-272026-05-04
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
Narlumosbart, Denosumab - Giant Cell Tumor of Bone
Phase 3Not yet recruitingShanghai JMT-Bio Inc.1462023-04-012023-04-19

Showing 20 of 158. Sign in to see all of them.

Narrower conditions

Gastrointestinal Stromal Tumors (38)  ·  Sarcoma (26)  ·  Myofibroma (19)  ·  Osteosarcoma (19)  ·  Liposarcoma (16)  ·  Sarcoma, Synovial (15)  ·  Fibrosarcoma (14)  ·  Brenner Tumor (13)  ·  Dupuytren Contracture (13)  ·  Histiocytoma, Malignant Fibrous (13)  ·  Leiomyosarcoma (13)  ·  Ovarian Neoplasms (13)  ·  Hemangiosarcoma (12)  ·  Neurofibrosarcoma (11)  ·  Leiomyoma (9)

Broader conditions

Neoplasms by Histologic Type (156)  ·  Neoplasms, Connective and Soft Tissue (155)  ·  Neoplasms (149)  ·  Neoplasms, Fibrous Tissue (54)  ·  Skin and Connective Tissue Diseases (42)  ·  Digestive System Diseases (40)  ·  Digestive System Neoplasms (40)  ·  Gastrointestinal Diseases (38)  ·  Gastrointestinal Neoplasms (36)  ·  Connective Tissue Diseases (35)  ·  Neoplasms, Bone Tissue (30)  ·  Neoplasms by Site (27)  ·  Pathological Conditions, Signs and Symptoms (27)  ·  Female Urogenital Diseases (26)

Interventions

Imatinib Mesylate (21)  ·  Doxorubicin (20)  ·  Ifosfamide (15)  ·  Paclitaxel (11)  ·  Radiotherapy (10)  ·  Sunitinib (9)  ·  Carboplatin (8)  ·  Cisplatin (8)  ·  Etoposide (8)  ·  Microbial Collagenase (7)  ·  Bevacizumab (6)  ·  Cyclophosphamide (6)  ·  Methotrexate (6)  ·  Disulfides (5)  ·  Immunoglobulin G (5)

Sponsors

National Cancer Institute (NCI) (13)  ·  European Organisation for Research and Treatment of Cancer - EORTC (9)  ·  Gynecologic Oncology Group (7)  ·  Children's Oncology Group (5)  ·  Endo USA Inc., a Keenova Therapeutics Company (5)  ·  Novartis Pharmaceuticals (5)  ·  AB Science (4)  ·  Deciphera Pharmaceuticals, LLC (4)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  InSightec (3)  ·  Pfizer (3)  ·  Philips Healthcare (3)  ·  Asan Medical Center (2)  ·  Blueprint Medicines Corporation (2)  ·  Children's Cancer Hospital Egypt 57357 (2)

Countries

United States (75)  ·  Canada (46)  ·  France (38)  ·  Germany (32)  ·  United Kingdom (32)  ·  Italy (31)  ·  Netherlands (29)  ·  Spain (29)  ·  South Korea (26)  ·  Australia (22)  ·  Poland (22)  ·  China (17)  ·  Belgium (16)  ·  Switzerland (16)  ·  Sweden (15)

Top investigators

Robert Min, M.D. (3)  ·  Anne Roberts, M.D. (2)  ·  Elizabeth David, MD (2)  ·  George Holland, M.D. (2)  ·  Mark Shaman, M.D. (2)  ·  Paolo G. Casali, MD (2)  ·  Veronica Urdaneta, MD, MPPH (2)  ·  Yoon-Koo Kang, MD, PhD (2)  ·  A.N. Van Geel, MD (1)  ·  Aaron R Weiss (1)  ·  Abha Gupta, MD (1)  ·  Achilleas Thoma, MD MSc FRCSC (1)

Results publications

PMID 37185961, PMID 31401903, PMID 21941283, PMID 30633128, PMID 16110020, PMID 16110036, PMID 16368440, PMID 16394300, PMID 16515585, PMID 16624552, PMID 16876399, PMID 17046465, PMID 17264340, PMID 17267204, PMID 17336514, PMID 17634494, PMID 17906207, PMID 18286501, PMID 18430468, PMID 18640939, PMID 18653326, PMID 19303137, PMID 19596139, PMID 19620483, PMID 19726771, PMID 20434400, PMID 20489620, PMID 21050498, PMID 21140148, PMID 21529904, PMID 21967070, PMID 22119995, PMID 22204724, PMID 22204725, PMID 22421192, PMID 22453568, PMID 22480131, PMID 22665534, PMID 22954508, PMID 23177515, PMID 23190833, PMID 23219660, PMID 24140183, PMID 24470559, PMID 24618336, PMID 24638003, PMID 24747207, PMID 24942631, PMID 24957256, PMID 25421877

NIH funding

U10CA180886 (6), U10CA027469 (5), U10CA180868 (5), U10CA098543 (4), 2008 (3), 2015 (3), 2004 (2), 2009 (2), 2014 (2), 2016 (2), 2025 (2), U10CA032102 (2), U10CA101165 (2), U10CA180830 (2), U10CA180888 (2)